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Abstract The group of dinucleoside polyphosphates encom-
passes a large number of molecules consisting of two nucle-
osides which are connected by a phosphate chain of variable
length. While the receptors activated by dinucleoside
polyphosphates as well as their degradation have been studied
in detail, its biosynthesis has not been elucidated so far. Since
endothelial cells released the dinucleoside polyphosphate uri-
dine adenosine tetraphosphate (Up4A), we tested cytosolic
proteins of human endothelial cells obtained from dermal
vessels elicited for enzymatic activity. When incubated with
ADP and UDP, these cells showed increasing concentrations
of Up4A. The underlying enzyme was isolated by chromatog-
raphy and the mass spectrometric analysis revealed that the
enzymatic activity was caused by the vascular endothelial
growth factor receptor 2 (VEGFR2). Since VEGFR2 but
neither VEGFR1 nor VEGFR3 were capable to synthesise
dinucleoside polyphosphates, Tyr-1175 of VEGFR2 is most
likely essential for the enzymatic activity of interest. Further,
VEGFR2-containing cells like HepG2, THP-1 and RAW264.7
were capable of synthesising dinucleoside polyphosphates.
VEGFR2-transfected HEK 293T/17 but not native HEK
293T/17 cells synthesised dinucleoside polyphosphates in vivo
too. The simultaneous biosynthesis of dinucleoside poly-
phosphates could amplify the response to VEGF, since
dinucleoside polyphosphates induce cellular growth via P2Y
purinergic receptors. Thus the biosynthesis of dinucleoside
polyphosphates by VEGFR2 may enhance the proliferative
response to VEGF. Given that VEGFR2 is primarily expressed
in endothelial cells, the biosynthesis of dinucleoside poly-
phosphates is mainly located in the vascular system. Since the
vasculature is also the main site of action of dinucleoside
polyphosphates, activating vascular purinoceptors, blood ves-
sels appear as an autocrine system with respect to dinucleoside
polyphosphates.We conclude that VEGFR2 receptor is capable
of synthesising dinucleoside polyphosphates. These mediators
may modulate the effects of VEGFR2 due to their proliferative
effects.
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Introduction
The group of dinucleoside polyphosphates encompasses a
large number of molecules consisting of two nucleosides
which are connected by a phosphate chain of variable
length, containing between two and seven phosphate moie-
ties. Dinucleoside polyphosphates have been isolated from
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numerous mammalian tissues and were shown to act both as
extracellular and intracellular mediators (e.g. [1–3]). P1, P4
diadenosine tetraphosphate (Ap4A) was the first diadenosine
polyphosphate isolated from mammalian tissue [4]. Some
years later, Ap4A was also isolated from human platelets
[5, 6]. Afterwards, diadenosine pentaphosphate (Ap5A),
diadenosine hexaphosphate (Ap6A) and diadenosine
heptaphosphate (Ap7A) were isolated from human platelets
and were characterised as potent vasoconstrictors [7].
The physiological and pathophysiological impact of
dinucleoside polyphosphates on, e.g. vascular tone regulation
[8], proliferation of VSMC as well as hemodynamic regula-
tion of the renal system was clarified in a large number of
studies in recent years (review in, e.g. [3, 9]). The physiolog-
ical and pathophysiological effects of dinucleoside poly-
phosphates are mediated by purinergic receptors. The
purinergic system and the agonists involved attract increasing
interest in cardiovascular research (e.g. [10–12]).
While the receptors activated by dinucleoside poly-
phosphates as well as their degradation have been studied in
detail, the biosynthesis of these compounds has not been
elucidated so far. Since endothelial cells released the
dinucleoside polyphosphate uridine adenosine tetraphosphate
(Up4A) [13, 14] (review in, e.g. [15]), we tested cytosolic
proteins of human endothelial cells obtained from dermal
vessels elicited for enzymatic activity in this study. We
were able to isolate and identify the enzyme synthesising
dinucleoside polyphosphates by this approach.
Methods
Chemicals
HPLC water (gradient grade) and acetonitrile (ACN) were
from Merck, all other substances from Sigma Aldrich.
Culture of endothelial cells
Human endothelial cells isolated from dermal microvessels
were immortalized to obtain a human microvascular endo-
thelial cell (HMEC-1) line that retains the morphologic,
phenotypic and functional characteristics of normal human
microvascular endothelial cells [13]. Experiments compar-
ing the phenotypic characteristics of HMEC-1 with primary
human dermal microvascular endothelial cells or human
umbilical vein endothelial cells revealed that HMEC-1 have
features of both small- and large-vessel endothelial cells
[13]. On day 0 we placed the cells into 175-cm2 cell culture
flasks (Nunc Inc., Germany) and stimulated the cells on
day 2 at approximately 70 % confluence. Confluent cultures
of HMEC-1 showed typical cobblestone appearance and
showed the characteristic expression of von Willebrand
factor, endothelial NO synthase, VEGF receptor 1 (FLT-1)
and the absence of smooth muscle α-actin staining. Further-
more, the endothelial cells were incubated in the presence of
Up4A (10 μmol/l) and VEGF (0.2 ng/μl) separately and in
combination. To investigate the effect of costimulation on
the enzymatic activity of VEGFR2, the endothelial cells
were cultivated in the presence of recombinant human (rh)
Ephrin A4 (0.4 ng/μl).
Stimulation of cultivated endothelial cells
Cell culture flasks of endothelial cells were washed three
times with a physiological salt solution. Afterwards, the cell
culture flasks of endothelial cells were exposed to shear
stress for 10 min by using a horizontally shaking machine
after addition of 10 ml physiologic salt solution. After
10 min, the supernatant was collected and pooled. The
supernatant was deproteinized with perchloric acid (final con-
centration 0.6 mol/l) and centrifuged at 3,500 U/min for 5 min
at 4 °C and neutralized with KOH to pH 9.5. The precipitated
proteins and the insoluble reaction product KClO4 were re-
moved by centrifugation (3,500 U/min; 4 °C; 5 min). For
control reactions, cell culture flasks of endothelial cells were
washed three times with 15 ml of a physiological salt solution
by avoiding shear stress, salt solution was added extremely
slowly. After the washing step, 15 ml physiological salt solu-
tion was added to the endothelial cells. Ten minutes later, the
supernatant was collected and pooled.
Chromatographic fractionation of the endothelial cytosol
Anion-exchange chromatography
K2HPO4 (final concentration 20 mmol/l) resolved in water
(pH 8) was added to endothelial cytosol. Afterwards, the
endothelial cytosol was fractionated by anion-exchanger
(column: Uno-Q1, 7×35 mm, Biorad, USA) using
K2HPO4 (20 mmol/l) in water (pH 8) as eluent A. The
substances retained by the anion-exchanger were eluated at
20 mmol/l K2HPO4 and 1 mol/l NaCl in water (pH 8) using
a step-wise gradient: 0–6 min, 0 % B; 6–6.1 min, 0–20 % B;
6.1–13.6 min, 20 % B; 13.5–13.7 min, 20–40 % B; 13.7–
21.2 min, 40 % B; 21.2–21.3 min, 40–60 % B; 21.3–
28.8 min, 60 % B; 28.8–28.9 min, 60–80 % B; 28.9–
36.4 min, 80 % B; 36.4–36.5 min, 80–100 % B; 36.5–
44.0 min, 100 % B; 44.0–44.1 min, 100–0 % B; 44.1–
53.1 min, 80 % B (flow rate, 1.5 ml/min; UV absorption
wavelength, 280 nm).
Cation-exchange chromatography
The fractions retained by the anion-exchanger were
chromatographed using a cation exchanger (column, Uno-
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S1, 7×35 mm, Biorad, USA). KH2PO4 in water (pH 3.5)
was used as eluent A. The substances retained by the cation-
exchanger were eluated by 20 mmol/l KH2PO4 and 1 mol/l
NaCl in water (pH 3.5) using a step-wise gradient: 0–7 min,
0 % B; 7–7.1 min, 0–50 % B; 7.1–13.1 min, 50 % B; 13.1–
13.2 min, 50–100 % B; 13.2–19.2 min, 100 % B; 19.2–
19.3 min, 100–0 % B; 19.3–29.3 min, 0 % B (flow rate,
1.0 ml/min; UV absorption wavelength, 280 nm).
Size-exclusion chromatography
The substances not retained by cation-exchange chromatog-
raphy were fractionated by size-exclusion chromatography.
The size-exclusion chromatography gel (Sephacryl S-100
High Resolution; 1000×16 mm, S100 HR, Pharmacia Bio-
Tech, Uppsala, Sweden) was equilibrated with 0.9 % NaCl
in water. The substances not retained by the cation-exchange
chromatography were loaded onto the column to elute it
with 0.9 % NaCl in water at a flow rate of 1 ml/min. The
elution was monitored with a UV-detector at 280 nm.
Anion-exchange chromatography
K2HPO4 (final concentration 20 mmol/l) resolved in water
(pH 8) was added to the endothelial cytosol. Afterwards, the
cation-exchange fraction with the capacity to synthesise
Up4Awas fractionated by anion-exchanger using the condi-
tions as described above. Instead of using a step-wise gra-
dient a linear gradient was used for elution the retained
substances: 0–8 min, 0 % B; 8–28 min, 0–35 % B; 28–
103 min, 35–70 % B; 103–103.2 min, 70–100 % B; 103.2–
108.2 min, 100 % B; 108.2–108.4 min, 100–0 % B; 104.2–
114.4 min, 0–0 % B (flow rate, 1.0 ml/min; UV absorption
wavelength, 280 nm).
Screening of chromatographic fractions for the enzymatic
actviy to biosyntheze Up4A
Sample preparation
One tenth of each fraction volume was desalted using size
exclusion gel columns (Mico Bio-Spin P-30 columns;
BioRad, USA). Briefly, the gel buffer was exchanged by
applying physiologic NaCl solution. The aliquots of the
samples were loaded onto the gel column and centrifuged
for 4 min at 1,000×g at room temperature. The filtrates were
immobilised and screened for enzymatic activities.
Immobilization of the enzymes
Endothelial cytosol (50 μl; protein concentration 0.5 mg/ml)
and 1/10 of the volume of each chromatographic fraction,
respectively, were both mixed with 50 μl NaHCO3 and
activated CNBr–Sepharose 6 MB beads (Amersham
Pharmacia Biotech, Germany). The mixtures were incubated
for 1 h at room temperature. After incubation, the beads
were washed three times with double-distilled water. The
beads were stored at 4 °C with sodium azide (0.05 % final
concentration) added.
Incubation of the immobilized enzymes with ADP and UDP
as substrates
Two-microliter beads containing the immobilized proteins
as well as both types of control beads were transferred into
400-ml reaction vials and washed three times with 10 ml
double distilled water to remove the sodium azide.
After each washing step, the liquid was removed using
10-μl thin tips with a diameter smaller than the diameter of
the beads to prevent loss of the beads during washing. Six
microlitre of a suspension containing the substrates ADP
and UDP (100 μmol/l each) was added. Aliquots (0.5 ml)
were removed from the reaction mixture after 5, 10 and
30 min for mass spectrometric analysis.
Detection of enzymatic activity by MALDI-MS
Aliquots from the reaction mixture and from the controls
were examined by MALDI-TOF/TOF- MS. For sample
preparation, 0.25 μl of the reaction mixture was mixed with
0.25 μl of matrix solution (50 mg/ml 3-hydroxypicolinic
acid in water). To this mixture cation-exchange beads (AG
50 W-X12, 200–400 mesh, Bio-Rad) equilibrated with
NH4
+ as counterion were added to remove Na+ and K+ ions.
The mixture was gently dried on a 384 format Anchor-Chip
target (Bruker-Daltonic, Germany) before analysing with
the mass spectrometer.
Matrix-assisted laser desorption/ ionisation mass
spectrometry (MALDI-MS) of Up4A contaning fractions
Mass spectrometric measurements were performed with a
Bruker Ultraflex TOF/TOF instrument (Bruker-Daltonics,
Germany). The instrument was equipped with a Smart
beamTM laser operating with a repetition rate of 100–
200 Hz. On average, the presented spectra are the sums of
300 single-shot spectra for MS mode, and 1,000 in MS/MS
mode. Argon was used as collision-induced dissociation
(CID) gas. Mass spectra of positively charged ions were
analysed in the reflector mode using delayed ion extraction.
Fragment ion spectra were recorded using the LIFT option
of the instrument. The calibration constants were deter-
mined using standard peptides prepared on positions adja-
cent to the sample, resulting in an error of <50 ppm for the
recorded mass spectra. The dinucleoside polyphosphate Ip5I
was added to the sample as internal standard in the case of
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kinetic measurements using MALDI mass spectrometry.
Hereby, local differences in the Up4A concentration on the
MALDI spot were eliminated [16].
SDS-PAGE electrophoresis
The protein composition of the protein fractions isolated
from endothelial cells were analyzed by SDS-PAGE using
the PhastGel gel-system (GE Healthcare, UK) and a gradi-
ent gel (10–15 % SDS gradient gel) and PhastGel gel SDS-
buffer strips (GE Healthcare, UK). Aliquots of the protein
fraction (20 ng/μl) were denatured by adding of SDS to a
final concentration of 2.5 % and β-mercaptroethanol to
5.0 % and heating at 95 °C for 5 min. SDS-buffer strips
contained 10 mmol/l TRIS/HCl, 1 mmol/l EDTA and 0.1 %
(w/v) SDS; the pH was preadjusted to 8.0. We used a voltage
of 250 V and amperage of 10 mA at 15 °C for fractionation
of the proteins. Following electrophoresis, automated silver
staining of SDS gels was performed by using the staining kit
“PhastGel SDS media” (GE Healthcare, UK) according to
the manufacturer’s protocol. Briefly, the samples were fixed
by 12.5 % glutardialdehyde and were stained with 0.5 %
silver nitrate (AgNO3). Formaldehyde (0.015 %) in 2.5 %
sodium carbonate was used as developer and 10 % acetic
acid and 10 % glycerol as preserving solution.
Identification of the isolated protein capable of synthesising
Up4A
The gel plugs were divided into small pieces and were incu-
bated in 100 μl 50 mmol/l ammoniumhydrogen carbonate
resolved in H2O/acetonitrile (1:1) for 10 min at 32 °C. After
removing the supernatant, the gel plugs were incubated in
100 μl 50 mmol/l ammoniumhydrogen carbonate in H2O for
10 min at 32 °C. The gel plugs were dehydrated with 50 μl
100 % acetronitrile and were dried by using a Speed Vac for
10 min. The gel plugs were incubated with aqueous ammoni-
um bicarbonate (50 mmol/l) and 0.05 %w/v trypsin of 24 h at
37 °C. The resulting peptides were concentrated and desalted
by utilizing the ZipTip C18 (Millipore, USA) technology using
water with 0.1 % trifluoroacetic acid (TFA). The elution was
done with 60 % acetonitrile in water with 0.1 % TFA. The
eluate was spread onto the MALDI target plate (MTP
groundsteelTM 400/384; Bruker-Daltonic, Germany) using
alpha-cyano-4-hydroxycinnamic acid (2.5 mg/ml) as matrix.
Matrix-assisted laser desorption / ionisation mass
spectrometry (MALDI-MS)
After digestion of the protein capable of synthesising Up4A,
the resulting peptides were resuspended in 10 μl H2O. 1 μL of
each fraction was prepared on a pre-structuredMALDI sample
support (MTP AnchorChipTM 400/384, Bruker Daltonics,
Germany) using theα-4-hydroxycinnamic acid affinity sample
preparation method [17]. The mass-spectrometer and all mass
spectrometric conditions were identical as described above.
Fragment ion spectra were recorded using the LIFT option of
the instrument. The calibration constants were determined
using standard peptides prepared on positions adjacent to the
sample, resulting in an error of <100 ppm for the recorded
mass spectra. The obtained MS/MS fragment data were com-
pared with data of the NCBInr protein database using Mascot
Search Engine, a search engine that uses mass spectrometry
data to identify proteins from primary sequence databases
(www.matrixscience.com). The identification was focused on
probability based molecular weight search (mowse) score of
the Mascot algorithm [18].
Enzymactic activity of VEGF receptor 1 and VEGF receptor 3
A recombinant human vascular endothelial growth factor
receptor (VEGFR1; FLT-1), (Sigma-Aldrich, Germany) and
a recombinant human vascular endothelial growth factor
receptor 3 protein (VEGFR3; FLT-4), (Sigma-Aldrich, Ger-
many) were immobilized to activated CNBr–Sepharose
6 MB beads (Amersham Pharmacia Biotech, Germany)
and were incubated with ADP and UDP (100 μmol/l each)
at 37 °C for 12 h. The resulting supernatants were analysed
in a time-depend manner by MALDI-TOF/TOF-mass-spec-
trometry as described above.
Sequence alignment of VEGF receptors VEGFR1, VEGFR2
and VEGFR3
In order to identify similarities and differences of the
three protein sequences, we applied a multiple alignment
using the CLUSTALW2 algorithm via the UniProt align-
ment tool [19]. CLUSTALW2 calculates the best global
alignment match for the chosen sequences and displays
identities, similarities and differences [20]. Similarity of
amino acids at each position of the alignment was scored
using the Gonnet protein weight matrices, and a gap
penalty was computed (gap open penalty=10, gap exten-
sion penalty=0.2). Based on this scoring, a hierarchical
clustering was computed with the neighbour-joining
method.
Characterisation of immobilised, authentic tyrosin kinase
receptors for enzymatic activities for Up4A biosynthesis
After the identification of the VEGFR2 protein, two recom-
binant VEGFR2 proteins (recombinant human vascular en-
dothelial growth factor receptor-2; Prospec-Tany Technogene,
Israel; recombinant human VEGFR2 receptor, expressed in
mouse NSO cells; Sigma-Aldrich, Germany) were cha-
racterised in detail. The recombinant VEGFR2 protein was
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incubated in the presence and absence of the VEGFR2 tyro-
sine kinase inhibitor N-(2,4-difluorophenyl)-N′-(4-(6,7-
dimethoxy-4-quinolyloxy)-2-fluorophenyl) urea (Ki8751;
Sigma-Aldrich, Germany) and the vascular endothelial
growth factor D (VEGF D human, recombinant, expressed
in Sf21 cells; Sigma-Aldrich, Germany), respectively.
Cultiviation of raw 264.7, THP-1 and HepG2 cells
The murine macrophage cell line RAW 264.7 was obtained
from the European Collection of Animal Cell Cultures (UK).
Cells were cultured in DMEM (4.5 g/L glucose) sup-
plemented with 10 % fetal calf serum (FCS) and 1 %
penicillin/streptomycin (Biochrom, Germany). Human liver
hepatocellular carcinoma cell line (HepG2) was cultivated in
DMEM (4.5 g/l glucose) supplemented with 10 % FCS and
1 % penicillin/streptomycin (Biochrom), too. HepG2 were
detached using TrypLE (Invitrogen, Germany). Human
acute monocytic leukemia cell line (THP-1) were cultivated
in RPMI 1640 (Life Technologies, Germany) supplemented
with 10 % FCS and 1 % penicillin/streptomycin (Biochrom).
Cultures were maintained in a humidified incubator in 5 %
CO2 at 37 °C.Cells were plated at a concentration of 100,000
cells/ml.
Transfection of huvec and hmec with siRNA
Human umbilical vein endothelial cells (HUVEC, pooled
donor) and immortalized human microvascular endothe-
lial cells (HMEC-1) were purchased from PromoCell
(Germany). The cells were cultivated in antibiotica-free
medium supplemented with human growth factors
(PromoCell, Germany). Before reaching confluence, cells
were detached with trypsin/EDTA, stopped with trypsin
neutralization solution (PromoCell, Germany) and seeded
in new culture flasks. The cells were cultivated in
MCDB-131 (CCPro, Germany) supplemented with 1 %
penicillin/streptomycin, 10 % fetal calf serum (FCS),
1 % glutamine, and 0.1 % hydrocortisone (Biochrom
AG, Germany) and were passaged every 3 days by
scraping, separating and seeding them in new culture
flasks. The cells were cultured in a humified atmosphere
at 37 °C and 5 % carbogen dioxide. The cells were
serum-starved 48 h pre-transfection (HMEC: 0 % FCS,
HUVEC: 0.5 % supplement mix). 0.5x106 (HUVEC) and
1.0×106 (HMEC) cells were transfected with pre-
designed silencer select siRNA against VEGFR2 or neg-
ative control siRNA with similar GC level (Life Tech-
nologies) using the Amaxa Nucleofector system with cell
specific nucleofector solutions (HUVEC nucleofector so-
lution or nucleofector solution Kit R; Lonza, Belgium).
Mock-transfected cells were used as a control. Transfec-
tion efficacy was verified via real-time PCR.
Detection of VEGFR2 after transfection of huvec
and HMEC-1 with siRNA
RNA from cells was isolated using the RNeasy Mini Kit
(Qiagen, Germany). RNA was reversely transcribed using
the iScript Kit (Biorad, Germany). For semi-quantitative
PCR performance, the GoTaq Green Master Mix (Promega,
Germany) was used using the following PCR program:
95 °C for 2 min, 95 °C for 45 s; 60 °C for 30 s, 72 °C for
45 s (30 repeats); 72 °C for 5 min, performed in the
Mastercycler Gradient (Eppendorf, Germany). PCR prod-
ucts were separated via electrophoresis on 1.5 % agarose gel
stained with ethidium bromide. For quantitative PCR, the
SYBR Green mastermix (Biorad, Germany) was used using
the following PCR program: 95 °C for 3 min, 95 °C for 15 s;
60 °C for 15 s, 72 °C for 1 min (39 repeats), followed by a
program for melting curve analysis performed in the CFX96
or CFX384 device (Biorad, Germany). The oligonucleotides
were synthesised by Tibmolbiol (Germany) and primer se-
quences were as follows: VEGFR2 (NM_002253.2) fwd: 5′-
CTT GCG CGC CGC AGA AAG TC-3′, rev: 5′-AGG CAA
ACC CAC AGA GGC GG- 3′.
Effect of Up4A on map-kinase, Akt and p38 mitogen-
activated protein kinase
HUVECs (Lonza) were cultured in endothelial cell culture
medium (Lonza) consisting of endothelial basal cell growth
medium containing (EBM), 2 % FBS and endothelial cell
growth supplements. Cells were cultured to 90 % conflu-
ence at 37 °C and 5 % CO2. Following serum starvation in
endothelial basal growth medium supplemented with 0.5 %
FBS for 24 h, cells were treated with Up4A concentrations
as indicated or 20 ng/mLVEGF (recombinant human VEGF
165, R&D Systems, 293-VE; Sigma-Aldrich, Germany) for
15 min. Cells were used from passage 2 to passage 4.
Antibodies were from: Phospho ERK1/2 (Thr202/Tyr204,
Cell Signaling, 9101, USA) and ERK1/2 (Cell Signaling,
9102); Phospho p38 MAPK (Thr180/Tyr182, BD, 612288
Germany) and p38 MAPK (BD, 612168); Phospho Akt
(Ser473, Cell Signaling, 9271, USA) and Akt (Cell Signaling,
9272); anti-mouse HRP-conjugated IgG (GE Healthcare,
NXA931 Germany) and anti-rabbit HRP-conjugated IgG
(GE Healthcare, NA934, Germany). Total cell lysates in
1.25 % NP40 buffer were prepared as described previously
[21]. According to manufacturer’s instructions utilizing the
Novex gel system (Invitrogen) and 4–12 % gradient gels,
equal protein amounts of each sample were subjected to
SDS-PAGE and transferred to nitrocellulose membranes
(Invitrogen) by electrotransfer. The membranes were blocked
in TBS containing 5 % milk and 0.1 % Tween-20 for 2 h
before overnight incubation at 4 °C with the appropriate
antibody diluted 1:2,000 in TBS containing 0.1 % Tween-
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20. Membranes were washed three times with TBS/0.1 %
Tween-20 before 1 h incubation with the appropriate second-
ary HRP conjugated antibody (dilution of 1:5,000). After
three washes in TBS/0.1 % Tween-20, membranes were de-
veloped using the ECL Luminogen-TMA6 reagents (GE
Healthcare, Germany) according to the manufacturer’s in-
structions. The G:Box System (Syngene, UK) was used to
image proteins on Western blots. Five independent experi-
ments were performed.
Expression of VEGFR2 receptor in the human embryonic
kidney cell line HEK293T
The full-length VEGFR2 kinase insert domain vector
(KDR; NCBI GenBank accession no. NM_002253.2)
encoding VEGFR2 cDNA under control of the CMV pro-
moter (expression vector pCDNA3, Invitrogen Corp.,
USA) was transfected into the human embryonic kidney
cell line HEK293T/17 (CRL-11268, ATCC, USA) for tran-
sient expression of KDR as follows. HEK293T cells were
grown up to about 70 % confluency in six 175-cm2 tissue
culture flasks in OptiMEM medium (Invitrogen Corp.)
supplemented with 10 % (v /v) fetal calf serum. The
VEGFR2 expression vector was mixed with FuGENE
HD transfection reagent according to the protocol provided
by the manufacturer (Promega Corp., USA) and diluted in
serum-free OptiMEM for transfection of the KDR vector
into the cells of three tissue culture flasks. In parallel, the
cells in the remaining flasks were transfected under the
same conditions using green fluorescence protein expres-
sion vector (GFP vector pmaxGFP, Lonza GmbH) in order
check transfection efficacy as well as to generate a control
batch to test for background formation of any dinucleoside
polyphosphate activity in HEK293T/17 acceptor cells not
carrying the VEGFR2 expression vector. After an incuba-
tion period of 48 h, cells were washed with phosphate
buffered saline (PBS) and the cells were scraped off and
suspended in 1.0 ml PBS resulting in two cell pools, one of
which expressing full length VEGFR2. Prior to harvesting,
transfection efficacy was checked by frequency of GFP
expressing cells which were cultivated in parallel based
on photographs made by using an Olympus 1×70 fluores-
cence microscope equipped with a NIBA filter. The cells
were lyophilized, immobilized and incubated with ADP
and UDP as described above.
Stimulation and analysis of cultured native and VEGFR2-
transfected human embryonic kidney cell line HEK293T/17
We washed cell culture flasks of native and VEGFR2-
transfected HEK293T/17 three times with a physiologi-
cal salt solution. To stimulate HEK293T/17 cells we
added tumor necrosis factor-alpha [22, 23] (TNF-alpha;
5 ng/ml) or phorbol–myristate–acetate [24, 25] (PMA;
1 μmol/l) in the presence and absence of ADP and
UDP (10 μmol/l each). The cell culture flasks of
HEK293T/17 cells were exposed to slight agitation for
15 min by using a horizontally shaking machine. After
15 min, the resulting supernatants were collected and
underwent deproteinization with perchloric acid (final
concentration 0.6 mol/l), centrifugation at 3,500 U/min
for 5 min at 4 °C and neutralization with KOH to
pH 9.5. We removed the precipitated proteins and the
insoluble reaction product KClO4 by centrifugation
(3,500 U/min; 4 °C; 5 min).
We added triethylammonium acetate (40 mmol/l final
concentration) was added to the supernatants and titrated
pH to 6.5. Next, we used a C18 reversed-phase column
(ChromolithTM Performance RP-18e 100–4.6, Merck,
Germany) to concentrate the supernatant of native and
transfected HEK293T/17 cells. We removed non-binding
substances with triethylammonium acetate. Then we eluted
binding substances stepwise with 20 % ACN in water at a
flow rate of 2.0 ml/min. We monitored the elution by mea-
suring the UV absorption at 254 nm. Last, we froze the
eluate at –80 °C and lyophilized it. We examined the lyoph-
ilized fractions from the reversed phase chromatography by
MALDI-TOF/TOF mass-spectrometry using the conditions
as described above.
Results
Isolation of the dinucleoside polpyhosphate synthesising
enzyme
The cytosolic, immobilised proteins obtained from human
endothelial cells showed the biosynthesis of Up4A when in-
cubated with ADP and UDP. To isolate the underlying en-
zyme, first, the cytosolic proteins were separated by anion-
exchange chromatography (Fig. 1a). Aliquots of each anion-
exchange chromatographic fraction were immobilised for fur-
ther incubation with ADP and UDP. The reaction products
were analysed by matrix-assisted laser desorption/ionisation
(MALDI) time-of-flight (TOF)/TOF-mass spectrometry. One
fraction of the anion-exchange chromatography eluting by
60 mmol/l aqueous NaCl solution had the capacity for
synthesising dinucleoside polyphosphates. The corresponding
fraction is labelled by an arrow in Fig. 1a. Figure 1b demon-
strates a corresponding MALDI-TOF/TOF-mass-spectrum of
synthesised Up4A. Next, this fraction was fractionated by
cation-exchange chromatography (Fig. 1c). The resulting frac-
tions were screened again for the enzymatic activity of inter-
est. The fraction not retained by the cation-exchanger (labelled
by an arrow in Fig. 1c) had the capacity of synthesising Up4A
from UDP and ADP. This fraction was further fractionated by
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size-exclusion (Fig. 1d) and anion-exchange chromatography
using a linear gradient (Fig. 1e).
Isolation of the dinucleoside polpyhosphate synthesising
enzyme
Since the heterogeneity of the cytosolic proteins was
significantly reduced by this column-chromatographic
steps (Fig. 1f; band a vs. band c), we fractioned the
fraction of interest by native gel-electrophoresis. The
fraction eluting at 93 min showed the enzymatic activity
of interest. Following SDS-PAGE fractionation, we fur-
ther analysed this fraction after tryptic degradation via
MALDI-TOF/TOF-mass spectrometry (Fig. 2a) and
identified the VEGFR2 protein using the probability
based molecular weight search (mowse) score of the
Mascot algorithm in this fraction (Fig. 2b).
Verification of enzymatic activity
To verify whether the detected enzymatic activity was attrib-
utable to the VEGFR2 receptor protein, we incubated a com-
mercially available VEGFR2 protein after immobilisation
with ADP and UDP. After an incubation period exceeding
10 min, we were able to detect a significant amount of Up4A
in the supernatant. Figure 2c demonstrates the MALDI-
TOF/TOF fragmentation mass spectrum of the enzymatically
synthesised Up4A in the reaction mixture. Each signal was
attributable to a fragment of Up4A as shown in Table 1,
Fig. 1 a Anion-exchange-chromatography of cytosolic proteins of
endothelial cells. The fraction labelled by an arrow was capable of
synthesising Up4A during incubation with ADP and UDP (100 μmol/l
each). b MALDI-TOF-TOF-mass spectrum of the cation-exchange
chromatographic fraction labelled in a. The molecular mass of
815.5 Da corresponds to the molecular mass of Up4A (M+H
+). c.
Cation-exchange chromatogram of the fraction labelled in a. The
fraction labelled by an arrow was capable of synthesising Up4A during
incubation with ADP and UDP (100 μmol/l each). d Size-exclusion
chromatography of the fraction not retained by the cation-exchanger
labelled by an arrow in c. The fraction labelled by an arrow was
capable of synthesising Up4A during incubation with ADP and UDP
(100 μmol/l each). e Linear gradient anion-exchange chromatography
of size-exclusion chromatographic fraction eluting at 82 min (d). The
fraction labelled by an arrow was capable of synthesising Up4A during
incubation with ADP and UDP (100 μmol/l each). f SDS-PAGE of
endothelial cytosolic proteins a after lysis of the cells, b after subse-
quent anion-exchange-chromatography a and c after anion-change
chromatographic fraction (e) capable of synthesising Up4A. The
labelled bands were caused by a protein capable of synthesising
Up4A after incubation with ADP and UDP (100 μmol/l each)
Fig. 2 a MALDI-TOF/TOF-fragmentation mass-spectrum of the iso-
lated protein with the enzymatic capacity to synthesise Up4A from
ADP and UDP (100 μmol/l each). b Probability based molecular
weight search (MOWSE) score of Mascot-Search using the MS/MS
data shown in Fig. 2a. c MALDI-TOF/TOF-fragmentation mass-spec-
trum of Up4A synthesised by VEGFR2 receptor after incubation of
ADP and UDP (100 μmol/l each).
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suggesting that Up4A is a synthesis product of the VEGFR2
protein.
Characterisation of enzymatic activities of the VEGFR2
To examine whether the enzymatic activity for the synthesis of
dinucleoside polyphosphates is specific for the VEGFR2 re-
ceptor or this activity is a general mechanism for VEGF
receptors, we immobilised commercially available VEGFR1,
VEGFR2 and VEGFR3 proteins and incubated these proteins
with ADP and UDP. Dinucleoside polyphosphates were ex-
clusively formed by reaction mixtures containing VEGFR2.
In contrast, reaction mixtures containing either VEGFR1 or
VEGFR3 did not contain dinucleoside polyphosphates, even
after prolonged incubation periods up to two hours (Electronic
supplementary material (ESM) Supplementary Fig. 2). There-
fore, the enzymatic activity for the synthesis of dinucleoside
polyphosphates is obviously specific for the VEGFR2
receptor.
Figure 3a demonstrates the time-dependent Up4A biosyn-
thesis through the VEGFR2 protein in the reaction mixture.
The Up4A production by the VEGFR2 receptor protein is
not directly caused by its tyrosine kinase activity since the
selective VEGFR2 tyrosine kinase inhibitor Ki8751 had no
effect on this activity (Fig. 3b). The inhibitory properties of
Ki8751 on the tyrosine kinase activity of the VEGFR2 protein
was validated by using random copolymer poly(Glu,Tyr) as a
positive control (ESM Supplementary Fig. 3).
Verfication of the phosphorylation activity of VEGFR2
To verify the specificity of the enzymatic activity of the
VEGFR2 protein, we incubated VEGFR2 with the tyrosine-
free peptide Kemptide (Leu–Arg–Arg–Ala–Ser–Leu–Gly) as
negative control and poly-Glu,Tyr as positive control. While
the VEGFR2 protein did not phosphorylate Kemptide (data
not shown), incubation of the VEGFR2 protein with poly-Glu,
Tyr demonstrates the tyrosine kinase activity (Fig. 3c). While
rhEphrin-A4 has a slight increasing effect on the proliferation
rate of HMEC cells (15.7±2.3 % above control), ephrin-A4
caused an 2.1-fold increase of the enzymatic activity for Up4A
synthesis of the immobilised HMEC (0.69±0.06 vs. 0.33±
0.09 (AU); p<0.05; N=3 each). In cultivated EC, presence of
rhEphrin-A4 cause an strong increased of the Up4A synthesis
rate and secretion rate compared to control conditions in the
absence of rhEphrin-A4 (0.0933±0.0328 vs. 0.0014±0.0003
(AU); p<0.05; N=3 each).
Specificity of the dinucleoside polyphosphate synthesising
activity of VEGFR2
The specificity of the VEGFR2 protein is also reflected by the
fact that the VEGFR2 protein synthesises (Fig. 3a) but does
not metabolise Up4A (Fig. 3d). However, the enzymatic ac-
tivity of the VEGFR2 protein for dinucleoside polyphosphate
formation is obviously not restricted to a small number or
selected of mononucleoside polyphosphates (Table 2). These
findings show that VEGFR2 is capable of synthesising all
known types of dinucleoside polyphosphates (Table 2).
Furthermore, the question arose whether the binding of
VEGF at the VEGFR2 receptor protein had an effect on this
enzymatic activity of the receptor. The presence of VEGF
has no significant effect on the enzymatic activity of interest
(Fig. 3e). The Up4A-synthesising activity is not a specific
activity of endothelial cells, since other VEGFR2 expressing
cells like HEPG2 [26, 27], THP-1 [28] and RAW264.7 [29]
cells are capable to synthesise Up4A by incubation with
ADP and UDP, too (Fig. 3f).
Table 1 Molecular masses of
Up4A fragments obtained by
MALDI-TOF/TOF-mass spec-
trometry. The mass signals were
obtained from MS/MS-spectrum
given in Fig. 2c. The middle
column: fragment masses mea-
sured by MALDI-TOF/TOF-
mass spectrometry; right col-
umn: fragment masses expected
theoretically from their respec-
tive structures (left column)
M+ protonated parent ion, U′
uracil, A adenosine, U uridine; p
phosphate group, e.g. Ap3 ATP;
w/o without






Ap1 w/o H2O 330.9 330.1
Ap2 w/o H2O 409.9 410.0
Ap2 427.9 428.0
Up3 w/o 2 H2O 450.0 448.1
Up3 w/o H2O 465.9 466.2
Ap3 w/o H2O 489.9 490.0
M w/o Up1 488.0 488.9
M w/o U′+2 H2O 717.9 719.0
M w/o U+H2O 551.5 552.0
Up4+3 H2O 617.9 618.1
Not interpreted 629.0
M w/o U′ and w/o H2O 682.9 682.9
Not interpreted 722.9
M 814.0 814.1
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Transfection of HMEC-1 cells with siRNA
For validation of the findings, HMEC-1 were transfected with
siRNA directed against the VEGFR2. The electroporation-
based transfection was controlled by real-time PCR andWest-
ern Blot. After immobilisation, the transfected cells were
incubated with ADP and UDP. The Up4A synthesis rates of
cells transiently lacking the VEGFR2 were significantly re-
duced compared to untransfected cells (Fig. 4a). After tran-
sient transfection with siRNA against VEGFR2, the Up4A
synthesis rate significantly decreased compared to mock-
transfected cells (Fig. 4a), confirming the assumption of
dinucleoside polyphosphate synthesis by VEGFR2. After
transient transfection with siRNA against VEGFR2, cultivat-
ed HMECs were not capable to release Up4A into the super-
natant after stimulation by shear stress. The use of HUVEC
cells instead of HMEC cells leads to comparable results (data
not shown).
Modulation of VEGFR2-induced pathways
Given that VEGFR2 mediates both the VEGF actions
and dinucleoside polyphosphate synthesis, the question
arose whether a dinucleoside polyphosphate such as
Up4A modulates VEGFR2 induced pathways. Up4A
modulates the phosphorylation of the mitogen-activated
Fig. 3 a. Time dependence of enzymatic Up4A production by
immobilised, recombinant VEGFR2 protein incubated with ADP and
UDP (100 μmol/l each; n=8). b Time dependence of enzymatic Up4A
production by immobilised, recombinant VEGFR2 protein incubated
with ADP and UDP (100 μmol/l each) in presence of the tyrosine
kinase inhibitor Ki8751(200 nmol/l) (n=5). c Representative MALDI-
mass spectra of poly-Glu,Tyr before (I) and after 5-min (II), 10-min
(III), 30-min (IV) and 60-min (V) incubation with immobilised,
recombinant VEGFR2 protein. The spectra demonstrate an character-
istic enzymatic activity of immobilised, recombinant VEGFR2 protein
by the enzymatic phosphorylation of the poly-Glu,Tyr. d Incubation of
Up4A with immobilised, recombinant VEGFR2 protein. The results
demonstrated no metabolic activity of the VEGFR2 protein for metab-
olism of Up4A. e Time dependence of enzymatic Up4A production by
immobilised, recombinant VEGFR2 protein incubated with ADP and
UDP (100 μmol/l each) in presence of VEGF (250 nmol/l) (n=11). f
Time-dependence of enzymatic Up4A production by cultivated HepG2
(solid square), THP-1 (up-pointing filled triangle) and RAW (down-
pointing filled triangle) cells by incubation of ADP and UDP
(100 μmol/l each; n=3)
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protein kinase p42/p44 (MAPkinase) (Fig. 4b), but has
neither an effect on endothelial p38-alpha MAPK nor
protein kinase B (AKT) (data not shown). Both VEGF
and Up4A caused a significant increase in the prolifer-
ation rate of cultivated HMEC (VEGF, 13.3±2.5; Up4A,
9.4±1.8), which was enhanced in case of a combined
application of the stimulants (14.9±2.9) (each percent-
age above control).
Transfection of HEK293t/17 cells with VEGFR2 expression
vector
Next, we treated HEK293T/17 cells with a VEGFR2
expression vector. The efficacy of transfection was esti-
mated based on a transient transfection conducted in
parallel using the expression vector pmaxGFP for green
fluorescent protein expression and subsequent counting
of fluorescently labeled cells by fluorescence microscopy.
After 48 h, approximately 60 % of cells expressed GFP
(Fig. 4c). While native HEK-293T/17 cells were not able
to synthesise Up4A from UDP and ADP, VEGFR2-
transfected immobilized cells significantly synthesised
a high amount of Up4A after adding UDP and ADP
(Fig. 4d).
Finally, we studied whether VEGFR2-transfected
HEK293/17 are capable to synthesise and to release dinu-
cleoside polyphosphates after stimulation in vivo, too. Tu-
mor necrosis factor-alpha (TNF-alpha) [22, 23] or PMA
[24, 25] stimulated the release of Up4A from VEGFR2-
transfected HEK 293/17, but not from native HEK 293/17
cells (Fig. 4e). The amount of Up4A in the supernatant of
stimulated VEGFR2-transfected HEK 293/17 was increased
in the presence of ADP und UDP (Fig. 4e). These results
show that VEGFR2 is essential for dinucleoside poly-
phosphate synthesis in vivo.
Discussion
Enzymatic activity of VEGF2 for synthesis of dinucleoside
polyphosphates
Endothelial cells showed increasing concentrations of
dinucleoside polyphosphate like Up4A when incubated with
ADP and UDP.Wewere able to isolate the underlying enzyme
to homogeneity by ion-exchange- and size-exclusion column
chromatography, as well as both native and SDS gel chroma-
tography to homogeneity. MALDI-TOF/TOF mass spectro-
metric analysis revealed that the enzymatic activity was
caused by the vascular endothelial growth factor receptor 2
(VEGFR2). VEGFR2 is a receptor tyrosine kinase and plays
an important role in angiogenesis (review in, e.g. [30]).
The biosynthesis of dinucleoside polyphosphates did not
decrease either in the presence of the selective VEGFR2-
tyrosine kinase inhibitor Ki8751 nor in the presence of
VEGF. Beside endothelial cells, further VEGFR2-containing
cells like HepG2, THP-1 and RAW264.7 were capable of
synthesising dinucleoside polyphosphates. VEGFR2-
transfected HEK 293T/17 but not native HEK 293T/17 cells
synthesised and released dinucleoside polyphosphates after
stimulation in vivo too. The dinucleoside polyphosphate
amount was increased in the presence of the mononucleoside
polyphosphates ADP and UDP.
VEGFR2 domains responsible for synthesis of dinucleoside
polyphosphates
After identification, the question arose which VEGFR2 do-
mains are responsible for the biosynthesis of dinucleoside
polyphosphates. The experiments with VEGF show that
the binding of this ligand does not affect dinucleoside
polyphosphate biosynthesis. Therefore, dinucleoside poly-
phosphate biosynthesis may be affected by the transmembrane
or the juxtamembrane domain. Moreover, it may be assumed
that mononucleotide phosphorylation is performed analogous
to tyrosine phosphorylation. As a consequence, the same
domain which is responsible for tyrosine autophosphorylation
may also synthesise dinucleoside polyphosphates. To further
investigate the domain responsible for dinucleoside
polyphosphate synthesis, we tested the various receptor sub-
types VEGFR1-3 for their ability to synthesise dinucleoside
polyphosphates.
VEGFR1, VEGFR2- and VEGF3 amino acid sequences we
computed a multiple alignment using the CLUSTALW algo-
rithm via the UniProt alignment tool [19]. Several functional
domains are shared by all 3 VEGFR subtypes, like carry sites
for proton acceptor (VEGFR1 at 1072, VEGFR2 at 1028 and
VEGFR3 at 1037) and ATP binding (VEGFR1 at 861,
VEGFR2 at 868 and VEGFR3 at 879) in their protein-kinase
domain. In addition, VGFR2 carries an additional, specific site
Table 2 Dinucleoside polyphosphates detected by MALDI-TOF/
TOF-mass spectrometry after incubation of mononucleoside









AMP+GMP Ap2A; Ap2G, Gp2G
AMP+UDP Ap2A; Ap3U, Up4U
ADP Ap4A
ADP+GMP Ap4A; Ap3G, Gp2G
ADP+UDP Ap4U; Ap4U, Up4U
ATP Ap6A
ATP+GMP Ap6A; Ap4G, Gp2G
ATP+UDP Ap6A; Ap5U, Up4U
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at tyrosine 1175, which has been identified previously as a
prominent interaction site and which is not present in the other
VEGFR subtypes. The result of the alignment is illustrated in
ESM Supplementary Fig. 1. Tyr-1175 of VEGFR2 is most
likely essential for the enzymatic activity for synthesis of
dinucleoside polyphosphates.
The VEGFR2-specific site at Tyr-1175 has been reported
before as a phosphorylation site which is important for inter-
action with PLCG1 [31] and SHB [32]. Holmqvist et al. have
performed co-immunoprecipitation experiments and detected
an interaction between SHB and VEGFR2 in human
telomerase-immortalized microvascular endothelial cells that
was important for VEGF signalling in endothelial cells and
regulated VEGF-induced formation of focal adhesion and cell
migration. In addition, Sase et al. examined the signal
transduction pathway downstream of VEGFR2 for endotheli-
al differentiation using an in vitro differentiation system of
mouse embryonic stem-cell-derived VEGFR2+ cells and
found an interaction of VEGFR2 to PLCG1, an inducer of
endothelial specification, via Tyr-1175 phosphorylation [31].
In contrast, this interaction was not detectable with VEGFR-3,
supporting a unique function of VEGFR2 in endothelial dif-
ferentiation from vascular progenitors. Therefore, it can be
assumed that this is also the functional domain mediating the
biosynthesis of dinucleoside polyphosphates.
Impact of dinucleoside polyphosphates on VEGFR2 actions
Given that VEGFR2 is one of the enzymes responsible for the
biosynthesis of dinucleoside polyphosphates, the question
Fig. 4 a Detection of Up4A-
synthesising activity of HMEC-
1 mock transfected (circle) and
(down-pointing filled triangle)
transient transfected with
siRNA against VEGFR2, or
(up-pointing filled triangle)
with negative control siRNA by
incubation of ADP and UDP
(100 μmol/l each). b
Quantification of Up4A effect
on p42/p44MAPK
phosphorylation measured
Western blot analysis. c
Transient transfection of HEK-
293T cells with green
fluorescence protein expression
vector as control vector after
24-h (upper panel) and 48-h
(lower panel) incubation. d
Detection of Up4A-synthesising
activity of native and VEGFR2-
transfected HEK-293T cells in
the presence of ADP and UDP
(100 μmol/l each). e
Quantification of Up4A in
supernatants of native HEK
293T/17 cells and VEGFR2-
transfected HEK 293T/17 cells
after stimulating with tumor
necrosis factor-alpha (TNF-
alpha) or phorbol-myristate-
acetate (PMA) and after
stimulation with TNF-alpha or
phorbol-myristate-acetate in
absence and presence of ADP
und UDP (100 μmol/l each)
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arises whether dinucleoside polyphosphates might play a role
in the context of VEGFR2 actions. Since VEGFR2 is involved
in the regulation of endothelial proliferation and angiogenesis,
the effect of Up4A as a characteristic dinucleoside poly-
phosphate on p42/p44MAPKwas investigated. The activation
level of p42/p44 MAPK increases steadily dependent on the
appliedUp4A concentration. The stimulation of HUVECswith
10 μmol/l Up4A results in an equivalent phosphorylation level
of the p42/p44 MAPK compared to 20 ng/ml VEGF. The
biosynthesis of dinucleoside polyphosphates by VEGFR2
may obviously stimulate the proliferative response of HUVEC
to VEGF. Since dinucleoside polyphosphates caused prolifer-
ative effects via P2Y purinergic receptors [3, 33], the simulta-
neous biosynthesis of dinucleoside polyphosphates could
amplify the response to VEGF, since dinucleoside poly-
phosphates are known to induce cellular growth via P2Y
purinergic receptors. Thus the biosynthesis of dinucleoside
polyphosphates by VEGFR2 may enhance the proliferative
response to VEGF.
Given that VEGFR2 is primarily expressed in endothelial
cells, the biosynthesis of dinucleoside polyphosphates is main-
ly located in the vascular system. Since the vasculature is also
the main site of action of dinucleoside polyphosphates, acti-
vating vascular purinoceptors, blood vessels appear as an
autocrine system with respect to dinucleoside polyphosphates.
Since VEGFR2 receptor is obviously capable to synthesise
dinucleoside polyphosphates, these mediators may modulate
the effects of VEGFR2 due to their proliferative effects in
general.
Conclusion
In conclusion, these findings are of interest for several
reasons:
1. The results demonstrate for the first time that VEGFR2
shows a yet unknown enzymatic activity
2. Dinucleoside polyphosphates are being synthesised en-
zymatically by VEGFR2.
3. Dinucleoside polyphosphates may modulate the prolif-
erative effects of VEGFR2 by an autocrine mechanism.
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